Clinical practice in non-small-cell lung cancer (NSCLC) has changed greatly since the
introduction of EGFR tyrosine kinase inhibitors (TKIs). Subsequent discovery of activating …

EGFR-directed therapies include the reversible specific tyrosine-kinase inhibitors (TKIs),
gefitinib and erlotinib, and the monoclonal antibody cetuximab. More recently, irreversible …

Since first reports, many publications showed data on incidence and characteristics of
epidermal growth factor receptor (EGFR) mutations in patients with non-small-cell lung …

The EGFR signalling pathway is relevant in many tumour types and is a successful
exploitable target for anticancer treatment, including for non-small-cell lung cancer …

Several phase 3 studies comparing the first-generation EGFR tyrosine kinase inhibitors
gefitinib and erlotinib as first-line treatments have been done in non-small-cell lung cancer …

This trial adds evidence to the hypothesis that second-generation TKIs are more effective, at
least with respect to progression-free survival, than are first-generation TKIs. However …

In a Comment1 on the OPTIMAL trial, 2 Tetsuya Mitsudomi suggests that differences in
clinical activity between the oral kinase inhibitors erlotinib and gefitinib in EGFR mutation …

This is a comment on" Afatinib for patients with lung adenocarcinoma and epidermal growth
factor receptor mutations (LUX-Lung 2): a phase 2 trial." Lancet Oncol. 2012 May; 13 (5) …

Reflection and Reaction www. thelancet. com/oncology Vol 11 May 2010 413 in specimens
taken during primary-tumour resection, and in those taken from the biopsy of recurrent …

The EGFR mutation was discovered as oncogenic driver in non-small-cell lung cancer
(NSCLC) more than 15 years ago. Unfortunately, resistance universally develops on EGFR …